Furthermore, our data indicated that transcranial LIPUS could be a qualified non-invasive technology to improve the impaired Fndc5/irisin signaling in hippocampus, and then treat the brain disorders related to CCH. The gene discussed is FNDC5; the disease is brain disorder.